In STEP 1, 4.5% of the semaglutide group discontinued because of gastrointestinal events versus 0.8% on placebo, and in STEP UP gastrointestinal adverse events were reported in 70.8% at 7.2 mg versus 61.2% at 2.4 mg and 42.8% on placebo
The Association of Diabetes Care and Education Specialists (ADCES) and American Diabetes Association recommend rotating injection sites within the same anatomical region and spacing injections appropriately to avoid tissue damage
Because semaglutide acts like GLP-1, it can further promote insulin secretion, which lowers your blood sugar
Omeprazole, while often well-tolerated, can also cause side effects, including headaches, stomach pain, and a higher risk of certain infections due to lower stomach acid
Everything is covered in one month of planning